FIRST TOTAL SYNTHESIS AND CYTOTOXICITY OF NATURALLY OCCURRING LESPEDEZOL E_1

Hua Sun,¹ Ya Nan Lei,¹ Wang Deng,¹ Hao Meng Wang,¹ Yu Ou Teng,¹ Hong Ye Zhao,¹ Qing Wei Yao,² and Peng Yu^{1*}

Lespedeza, a genus of the Fabaceae family, is widely distributed in Asia, Australia, and North America. In the last several decades, many flavonoids and isoflavonoids isolated from Lespedeza species have been reported for a variety of biological and pharmacological activities, such as hepatoprotective [1], antioxidant [2], antinematode [3], anticoccidial [4], and antitumor activity [5–7]. Lespedeza E_1 (1), a C_8 -geranylated isoflavonoid, was first isolated from the stem of Lespedeza homoloba in 1999 and was shown to exhibit antioxidant activity [2]. Recently, it was also isolated from Ficus benjamina and evaluated for its inhibitory activity on BACE1 [8]. In 2007, the methylated homologues of 1,8-C-geranyl-7-O-methylbiochanin A (3) and olibergin B were identified and isolated from the stems of Dalbergia species [9], but their biological activities have not been further evaluated.

Recent studies have shown that some natural geranylated flavonoid/isoflavonoid possess potent antitumor activities [10]. The development of convenient and efficient synthetic approaches for the preparation of large quantities of geranylated flavonoid/isoflavonoid and their analogues would be highly desirable for their biological studies. Here, we report the first total synthesis of the naturally occurring lespedezol E_1 and its methyl derivatives 5,7,4'-trimethyl-8-*C*-geranylisoflavone (**2**) and **3**.

In contemplating a general approach for the synthesis of C_8 -geranylated isoflavanone natural products, we envisaged a simple protocol involving the Pd-catalyzed Suzuki coupling of geranyl boronic esters [11] with a C_8 -iodo derivative of genistein. The latter is expected to be readily accessible based on our experience in the regioselective iodination of flavanoids [12, 13]. Our initial synthesis commenced with the fully methylated genistein **5** (Scheme 1, A). The Suzuki coupling reaction afforded **2** from regiospecific iodide **6**. However, attempted removal of the methyl groups without affecting the geranyl side chains proved unsuccessful. Thus, treatment of **2** in the presence of BCl₃ at 0°C for 30 min led to the formation of **3** in 85% yield, with demethylation occurring at the C_5 -position in accordance with the literature precedent that BCl₃ selectively demethylates the methoxyl group ortho to a carboxyl group [14]. Further demethylation of **3** using BCl₃ or BBr₃ was unsuccessful because the geranyl group was unstable under an extended reaction time (> 30 min) and higher reaction temperature (> 0°C). The all MOM-protected isoflavone **7** was then prepared using MOMCl with the hope that the geranyl side chains would be preserved under the reaction conditions for the deprotection of the MOM groups. Therefore, geranylated isoflavone **9** was converted to the naturally occurring **1** in 81% yield (Scheme 1, B).

All these synthetic products and the unsubstituted genistein (4) itself were evaluated for their cytotoxicity *in vitro* against tumor cell lines, including K562, HepG2, HT-29, and MGC-803 (Table 1). The preliminary SAR study showed that the presence of a geranylated side chain on the isoflavonoid structure can enhance the cytotoxic activity of 1 by more than tenfold for K562, HepG2, and HT-29, and sixfold for MGC-803 when compared to that of 4. A similar conclusion can be drawn when comparing the trimethylated product 2 with 5. However, the 7,4'-dimethyl product 3 lost potency.

In summary, we have achieved the first and facile total synthesis of lespedezol E_1 starting from genistein in four steps with 47% overall yield. This approach allows the regioselective introduction of geranyl side chains in the natural isoflavonoid in good yield. Furthermore, a comparison of the cytotoxic activity of the geranylated isoflavonoid with its mother core showed that the geranyl is important to improve the antitumor activity *in vitro*. The synthesis of additional modified 1-analogues to establish SARs and generate an optimized antitumor lead is in progress.

 Key Laboratory of Industrial Fermentation Microbiology of Ministry of Education, Tianjin Key Laboratory of Industry Microbiology, Tianjin University of Science and Technology, 300457, Tianjin, P. R. China, e-mail: yupeng@tust.edu.cn;
Sphinx Scientific Laboratory, 1250 East State Street, Sycamore, 60178, Illinois, USA. Published in *Khimiya Prirodnykh Soedinenii*, No. 5, September–October, 2016, pp. 764–766. Original article submitted November 13, 2014.

TABLE 1. Cytotoxicity in vitro of Lespedezol E1 and Its Derivatives (IC50, µM)*

Compound	K562	HepG2	HT-29	MGC-803
1	3.14 ± 0.52	19.58 ± 3.59	4.45 ± 1.87	8.30 ± 4.50
2	7.78 ± 2.16	25.19 ± 3.39	25.21 ± 2.16	16.72 ± 4.27
3	47.25 ± 6.78	>100	>100	>100
4	59.64 ± 6.14	>100	>100	48.88 ± 9.17
5	32.65 ± 2.24	87.04 ± 0.01	79.91 ± 4.12	>100
13	52.68 ± 6.85	>100	>100	>100
Camptothecin**	0.13 ± 0.04	>10	0.38 ± 0.03	0.58 ± 0.02

*Results are the average of three independent experiments, each performed in duplicate. Standard deviations were below $\pm 10\%$. **Reference compound.



1: $R_2 = R_3 = R_4 = H$; 2: $R_2 = R_3 = R_4 = CH_3$ 3: $R_2 = R_4 = CH_3$, $R_3 = H$; 4: $R_1 = R_2 = R_3 = R_4 = H$ 5: $R_1 = H$, $R_2 = R_3 = R_4 = CH_3$; 13: $R_1 = R_3 = H$, $R_2 = R_4 = CH_3$



1: R = H; 2, 3, 5, 6: $R = CH_3$; 7 – 9: R = MOM

A: *a*. CH₃I, K₂CO₃, DMF, 40°C, 4 h, 95%; *b*. NIS, DMF, 70°C, 4 h, 94%; *c*. Pd(dppf)·Cl₂, Cs₂CO₃, DMF, 110°C, microwave, 2 h, 66–76 %; *d*. BCl₃, DCM, 0°C, 30 min, 85 %. **4→5→6→2→3**

B: *a*. MOMCl, 60% NaH, DMF, 0°C − r.t., 2 h, 87%; *b*. NIS, DCM, r.t., 2 h, 93%; *c*. Pd(dppf)·Cl₂, Cs₂CO₃, DMF, 110°C, microwave, 2 h, 71–75 %; *d*. 2M·HCl, MeOH/THF (5:1), 0–60°C, 81%. **4**→7→**8**→**9**→1

Scheme 1. Synthesis of compounds 2 and 3 (A) and compound 1 (B).

Lespedezol E_1 (1). Yellow solid. ¹H NMR (400 MHz, MeOD-d₄, δ , ppm, J/Hz): 1.52 (3H, s), 1.57 (3H, s), 1.79 (3H, s), 1.97 (2H, t, J = 7.2), 2.05 (2H, m, J = 7.6), 3.41 (2H, d, J = 7.2), 5.01 (1H, t, J = 6.8), 5.20 (1H, t, J = 6.8), 6.27 (1H, s), 6.84 (2H, d, J = 8.8), 7.37 (2H, d, J = 8.4), 8.12 (1H, s). ¹³C NMR (100 MHz, MeOD-d₄, δ , ppm): 14.8, 16.2, 20.7, 24.4, 26.1, 39.3, 98.1, 104.8, 106.5, 114.8, 122.0, 122.1, 122.9, 123.9, 130.0, 130.6, 134.5, 153.4, 155.4, 157.3, 160.0, 161.8, 181.2. LR-MS(ESI) *m/z* 407.1 [M + H]⁺.

5,7,4'-Trimethyl-8-*C***-geranylisoflavone (2)**. White solid. ¹H NMR (400 MHz, CDCl₃, δ, ppm, J/Hz): 1.56 (3H, s), 1.62 (3H, s), 1.79 (3H, s), 1.97 (2H, t, J = 8.8), 2.14 (2H, m), 3.45 (2H, d, J = 7.2), 3.82 (3H, s), 3.94 (3H, s), 3.96 (3H, s), 5.05

(1H, t, J = 6.8), 5.17 (1H, t, J = 6.8), 6.42 (1H, s), 6.93 (2H, d, J = 8.8), 7.49 (2H, d, J = 8.8), 7.82 (1H, s). ¹³C NMR (100 MHz, CDCl₃, δ , ppm): 16.1, 17.6, 21.6, 25.6, 26.6, 19.7, 55.3, 55.8, 56.4, 91.9, 109.6, 109.9, 113.6, 121.8, 124.2, 124.5, 125.1, 130.3, 131.3, 135.4, 150.2, 156.5, 159.3, 159.8, 160.8, 176.0. HR-MS(ESI) *m/z* calcd for C₂₈H₃₃O₅ [M + H]⁺ 449.2323, Found 449.2323.

5-Hydroxyl-7,4'-dimethyl-8-*C***-geranylisoflavone (3)**. Yellow solid. ¹H NMR (400 MHz, CDCl₃, δ, ppm, J/Hz): 1.57 (3H, s), 1.63 (3H, s), 1.79 (3H, s), 1.97 (2H, t, J = 7.2), 2.06 (2H, m), 3.42 (2H, d, J = 6.8), 3.84 (3H, s), 3.90 (3H, s), 5.05 (1H, t, J = 7.2), 5.16 (1H, t, J = 6.2), 6.42 (1H, s), 6.98 (2H, d, J = 8.0), 7.47 (2H, d, J = 8.0), 7.92 (1H, s), 12.94 (1H, s). ¹³C NMR (100 MHz, CDCl₃, δ, ppm): 16.0, 17.6, 21.3, 25.6, 26.6, 39.7, 55.3, 56.0, 95.2 105.7, 107.9, 114.1, 121.8, 123.0, 123.1, 124.2, 130.1, 131.3, 135.5, 152.8, 154.6, 159.7, 161.0, 162.9, 181.3. LR-MS(ESI) *m/z* 435.2 [M + H]⁺.

ACKNOWLEDGMENT

We thank the Chinese National Natural Science Foundation (21502138), the International Science & Technology Cooperation Program of China (No. 2013DFA31160) and the Scientific Research Foundation of Tianjin University of Science & Technology (No. 20110115).

REFERENCES

- 1. S. M. Kim, K. Kang, E. H. Jho, Y. J. Jung, C. W. Nho, B. H. Um, and C. H. Pan, *Phytother. Res.*, 25, 1011 (2011).
- 2. T. Miyase, M. Sano, K. Yoshino, and K. Nonaka, *Phytochemistry*, **52**, 311 (1999).
- J. M. Burke, N. C. Whitley, D. A. Pollard, J. E. Miller, T. H. Terrill, K. E. Moulton, and J. A. Mosjidis, *Vet. Parasitol.*, 181, 345 (2011).
- 4. J. M. Burke, J. E. Miller, T. H. Terrill, S. T. Orlik, M. Acharya, J. J. Garza, and J. A. Mosjidis, *Vet. Parasitol.*, **193**, 39 (2013).
- L. Li, H. K. Wang, J. J. Chang, A. T. McPhail, D. R. McPhail, H. Terada, T. Konoshima, M. Kokumai, M. Kozuka, J. R. Estes, and K. H. Lee, *J. Nat. Prod.*, 56, 690 (1993).
- T. Konoshima, M. Takasaki, M. Kozuka, H. Tokuda, H. Nishino, E. Matsuda, and M. Nagai, *Biol. Pharm. Bull.*, 20, 865 (1997).
- 7. C. Ito, M. Itoigawa, H. T. Tan, H. Tokuda, X. Yang Mou, T. Mukainaka, T. Ishikawa, H. Nishino, and H. Furukawa, *Cancer Lett.*, **152**, 187 (2000).
- 8. J. Dai, D. Shen, W. Y. Yoshida, S. M. Parrish, and P. G. Williams, *Planta Med.*, 78, 1357 (2012).
- S. I. Khalivulla, B. A. K. Reddy, D. Gunasekar, M. M. Murthy, T. P. Rao, A. Blond, and B. Bodo, *Nat. Prod. Commun.*, 2, 1109 (2007).
- V. Dominguez-Villegas, V. Dominguez-Villegas, M. L. Garcia, A. Calpena, B. Clares-Naveros, and M. L. Garduno-Ramirez, *Nat. Prod. Commun.*, 8, 177 (2013).
- 11. Guillaume Dutheuil, Nicklas Selander, Kalman J. Szabo, and Varinder K. Aggarwal, *Synthesis*, 14, 2293 (2008).
- 12. K. Lu, J. Chu, H. M. Wang, X. L. Fu, D. W. Quan, H. X. Ding, Q. W. Yao, and P. Yu, *Tetrahedron Lett.*, **54**, 6345 (2013).
- 13. H. M. Wang, Z. H. Yan, Y. N. Lei, K. Sheng, Q. W. Yao, K. Lu, and P. Yu, *Tetrahedron Lett.*, 55, 897 (2014).
- 14. K. Q. Wu, L. H. Xu, L. L. Weng, and H. Zheng, Chem. Res. Appl., 16, 165 (2004).